HUE054741T2 - Húgysavasság vagy köszvény megelõzése vagy kezelése - Google Patents
Húgysavasság vagy köszvény megelõzése vagy kezeléseInfo
- Publication number
- HUE054741T2 HUE054741T2 HUE16742632A HUE16742632A HUE054741T2 HU E054741 T2 HUE054741 T2 HU E054741T2 HU E16742632 A HUE16742632 A HU E16742632A HU E16742632 A HUE16742632 A HU E16742632A HU E054741 T2 HUE054741 T2 HU E054741T2
- Authority
- HU
- Hungary
- Prior art keywords
- gout
- prevention
- treatment
- uric acid
- uric
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229940116269 uric acid Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054741T2 true HUE054741T2 (hu) | 2021-09-28 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16742632A HUE054741T2 (hu) | 2015-01-30 | 2016-01-28 | Húgysavasság vagy köszvény megelõzése vagy kezelése |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10322132B2 (https=) |
| EP (1) | EP3251675B1 (https=) |
| JP (1) | JP6678685B2 (https=) |
| KR (1) | KR102128810B1 (https=) |
| CN (1) | CN107206002B (https=) |
| AU (1) | AU2016212625B2 (https=) |
| BR (1) | BR112017016065A2 (https=) |
| CA (1) | CA2973746C (https=) |
| CY (1) | CY1124383T1 (https=) |
| DK (1) | DK3251675T3 (https=) |
| EA (1) | EA034139B1 (https=) |
| ES (1) | ES2881872T3 (https=) |
| HR (1) | HRP20211007T1 (https=) |
| HU (1) | HUE054741T2 (https=) |
| IL (1) | IL253726B2 (https=) |
| LT (1) | LT3251675T (https=) |
| MA (1) | MA41431B1 (https=) |
| MX (1) | MX380301B (https=) |
| PL (1) | PL3251675T3 (https=) |
| PT (1) | PT3251675T (https=) |
| SG (2) | SG11201705889VA (https=) |
| SI (1) | SI3251675T1 (https=) |
| SM (1) | SMT202100359T1 (https=) |
| TW (1) | TWI680761B (https=) |
| WO (1) | WO2016119570A1 (https=) |
| ZA (1) | ZA201704600B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12566174B2 (en) | 2017-05-11 | 2026-03-03 | The Research Foundation For The State University Of New York | Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid |
| US20260035370A1 (en) | 2023-02-27 | 2026-02-05 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
| CN116650490B (zh) * | 2023-06-07 | 2025-05-20 | 中国人民解放军海军军医大学 | 化合物mt-1207在降低尿酸方面的应用 |
| EP4497439A1 (en) * | 2023-07-28 | 2025-01-29 | Universitat de les Illes Balears | Compounds for the treatment or prevention of gout |
| TWI902254B (zh) * | 2024-05-16 | 2025-10-21 | 新加坡商珊頓醫藥科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| CN101103030B (zh) | 2004-02-14 | 2010-10-13 | 史密丝克莱恩比彻姆公司 | 具有hm74a受体活性的药物 |
| CN101479273B (zh) * | 2006-06-23 | 2011-11-30 | 英赛特股份有限公司 | 作为hm74a激动剂的嘌呤酮衍生物 |
| KR20090025262A (ko) * | 2006-06-23 | 2009-03-10 | 인사이트 코포레이션 | Ｈｍ７４ａ 아고니스트로서 푸리논 유도체 |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active Active
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 SM SM20210359T patent/SMT202100359T1/it unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-28 MX MX2017009853A patent/MX380301B/es unknown
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 HR HRP20211007TT patent/HRP20211007T1/hr unknown
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/zh not_active Ceased
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283837A (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
| LT3334422T (lt) | Kanabidiolio rūgšties panaudojimas epilepsijos gydymui | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| PL3212174T3 (pl) | Sposoby leczenia zakażeń wirusem filoviridae | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| EP3563853C0 (en) | COMPOSITION OF MANNURONIC DIACID | |
| EP3386505A4 (en) | AZA-BENZIMIDAZOLINHIBITORS OF PAD4 | |
| DK3203997T3 (da) | Valproinsyre til behandling eller forebyggelse af patologiske tilstande forbundet med overskydende fibrinaflejring og/eller trombedannelse | |
| EP3503904C0 (en) | ASCAROSIDE TREATMENT OF EOSINOPHIL ESOPHAGITIS | |
| IL255185A0 (en) | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto | |
| DK3481819T3 (da) | Forbindelser og anvendelse deraf til reducering af urisyreniveauer | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| EP3365477A4 (en) | CORROSION RESISTANCE | |
| DK3220952T3 (da) | Fremgangsmåde til behandling eller forebyggelse af slagtilfælde | |
| IL256111B1 (en) | Pac–1 combination therapy | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| PL3160913T3 (pl) | Sposób oczyszczania osadu biologicznego | |
| IL253726B1 (en) | Preparations for the treatment of inflammatory diseases related to uric acid | |
| DK3406258T3 (da) | Medikament til anvendelse til behandling af urinsyregigt | |
| DK3182980T3 (da) | Behandling af glykosyleringsmangelsygdomme | |
| DK3229811T3 (da) | Forebyggelse og behandling af betændelseslidelser | |
| DK3200783T3 (da) | Behandling af erytromelalgi | |
| GB201515244D0 (en) | Treatment of inflammatory disease or condition |